ZYME Q4 2024 Earnings — Zymeworks Inc. Revenue & Financial Results | Market Cap Arena

ZYMEZymeworks Inc.

$2B

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$31M+83.3% YoY

Gross Profit

$31M100.0% margin

Operating Income

-$22M-71.6% margin

Net Income

-$24M-75.8% margin

EPS (Diluted)

$-0.31

QoQ Revenue Growth

+93.9%

Cash Flow

Operating Cash Flow

-$42M

Free Cash Flow

-$42M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$463M

Total Liabilities

$124M

Stockholders' Equity

$339M

Cash & Equivalents

$66M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$31M	$17M	+83.3%
Gross Profit	$31M	$17M	+83.3%
Operating Income	-$22M	-$23M	+5.1%
Net Income	-$24M	-$14M	-62.3%

Revenue Segments

Upfront Fee

$18M100%